Analysis of Drug and Health Resource Use Before and After COVID-19 Lockdown in a Population Undergoing Treatment for Depression or Anxiety
Resumen: IntroductionThe arrival of the COVID-19 pandemic modified the functions of Primary Care (PC) teams, which were forced to focus their resources on the diagnosis and treatment of SARS-CoV-2 infected patients. The disrupted healthcare of individuals with pre-existing mental disorders (depression or anxiety), as well as the psychological decompensation resulting from the lockdown caused by the COVID-19 pandemic, may have modified the use of drugs and health resources by these patients. The aim of this study is to determine the changes in these parameters, between the 6 months prior to the lockdown (09/14/2019 to 03/15/2020) and the 6 months following its end (05/03/2020 to 11/04/2020), in a population undergoing active treatment for depression or anxiety, according to the electronic clinical record.Materials and MethodsReal world data observational study of 110,694 individuals aged >16 years suffering from active or undergoing treatment for depression or anxiety according to the electronic medical records of the Aragon Regional Health Service (Spain). Pharmacological variables [daily dose per inhabitant (DHD) dispensed by pharmacies of: anxiolytics, hypnotics/sedatives, and antidepressants] and variables related to the use of healthcare resources (number of primary and specialized healthcare visits) were considered. Student’s T-tests for paired samples were performed to analyze differences between periods (pre–post). The level of significance was established at 5% (p < 0.05).ResultsThe use of anxiolytic drugs increased as compared to its use over the 6 months prior to the lockdown. In contrast, the consumption of antidepressants was found to decrease. The use of health resources continued to be below pre-pandemic levels, 6 months post-lockdown end.ConclusionChanges in the use of health resources could have a negative impact on the parameters of these diseases. The increase in drug use, especially benzodiazepines, may suggest a worsening of the symptoms during the lockdown and in the subsequent months. It is a worrying sign, which points to the growth of this public health problem and the need for its prevention.
Idioma: Inglés
DOI: 10.3389/fpsyg.2022.861643
Año: 2022
Publicado en: Frontiers in Psychology 13 (2022), 861643 [8 pp.]
ISSN: 1664-1078

Factor impacto JCR: 3.8 (2022)
Categ. JCR: PSYCHOLOGY, MULTIDISCIPLINARY rank: 34 / 147 = 0.231 (2022) - Q1 - T1
Factor impacto CITESCORE: 4.5 - Psychology (Q2)

Factor impacto SCIMAGO: 0.891 - Psychology (miscellaneous) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B21-20R-GAIAP
Tipo y forma: Article (Published version)
Área (Departamento): Área Psicología Social (Dpto. Psicología y Sociología)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.


Exportado de SIDERAL (2024-03-18-15:22:40)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Psicología Social



 Record created 2022-12-21, last modified 2024-03-19


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)